PHK
TCRT icon

Point72 Hong Kong’s Alaunos Therapeutics TCRT Stock Holding History

Point72 Hong Kong’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-54
Closed -$5K – 2390
2022
Q1 		$5K Buy
+54
New +$6.93K ﹤0.01% 1685
2021
Q3 		– Sell
-21
Closed -$8K – 2421
2021
Q2 		$8K Buy
+21
New +$9.8K ﹤0.01% 1767
2020
Q4 		– Sell
-1
Closed -$1K – 2038
2020
Q3 		$1K Buy
+1
New +$442 ﹤0.01% 1144

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Point72 Hong Kong's TCRT Position: Q2 2022 in Review

Point72 Hong Kong sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 54 shares — an estimated $5K sold.

Point72 Hong Kong first reported a position in TCRT in Q3 2020 and held it in 3 quarters. The position peaked at $8K in Q2 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Point72 Hong Kong reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 54 Alaunos Therapeutics shares in Q2 2022, an estimated $5K.
  • Point72 Hong Kong first reported a position in Alaunos Therapeutics in Q3 2020 and held it in 3 quarters.
  • Point72 Hong Kong's Alaunos Therapeutics position peaked at $8K in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.